Key result
Three manufacturing lots of the novel EV71 vaccine demonstrated equivalence in immunogenicity among healthy children, with 95% CIs of the log difference in GMTs between -0.176 and 0.176.
Why the study?
Does the novel inactivated EV71 vaccine demonstrate lot-to-lot consistency, immunogenicity, and safety in healthy children aged 6 to 59 months?
RCT (n=1,400)
Double-blind
Randomized
Does the novel inactivated EV71 vaccine demonstrate lot-to-lot consistency, immunogenicity, and safety in healthy children aged 6 to 59 months?
The novel inactivated EV71 vaccine demonstrates lot-to-lot manufacturing consistency, high immunogenicity, and a favorable safety profile in children.
Answers are grounded in this paper and cite their sources.
Demonstrates manufacturing consistency for EV71 vaccine; supports regulatory approval and pediatric immunization programs.
The determination of lot-to-lot consistency in the manufacturing process is a mandatory step in the clinical development of the novel enterovirus 71 (EV71) vaccine. A phase III, randomized, placebo-controlled, double-blind trial assessed the lot consistency, immunogenicity, and safety of the EV71 vaccine in children aged 6 to 59 months. Healthy children (n = 1,400) received one of three lots of the EV71 vaccine containing 400 U of EV71 antigen or a placebo at days 0 and 28. Blood samples were collected before dose 1 and at 28 days after dose 2 (day 56) for an anti-EV71 neutralizing antibody (NTAb) assay. The geometric mean titer (GMT) and the seropositivity rates (with titers of ≥1:8) were compared at day 56. After each dose, the solicited injection site and general adverse events (AEs) were recorded for 7 days, and unsolicited AEs were recorded for 28 days. At day 56, the seropositivity rates ranged from 99.7% to 100% for the vaccine groups. The NTAb GMTs for the vaccine were 140.3 (95% confidence interval [CI], 117.8 to 167.1), 141.5 (95% CI, 118.0 to 169.6), and 146.6 (95% CI, 122.5 to 175.3). The two-sided 95% CI of the log difference in GMTs between the pairs of lots were between -0.176 and 0.176, therefore meeting the predefined equivalence criteria. The percentages of subjects reporting any injection site AEs, general AEs, or serious AEs were similar across the four vaccination groups. In conclusion, the demonstration of consistency between the manufacturing lots confirms for the purposes of clinical development the reliability of the EV71 vaccine production process. (This study has been registered at ClinicalTrials.gov under registration no. NCT01636245.).
No takes yet. Share an insight, caveat, or question.
Hu et al. (2013) conducted an RCT in Healthy children (n=1,400). Inactivated enterovirus 71 (EV71) vaccine vs. Placebo was evaluated on Lot consistency based on anti-EV71 neutralizing antibody geometric mean titer (GMT) and seropositivity rates at day 56 (log difference in GMTs, 95% CI -0.176 to 0.176). Three manufacturing lots of the novel EV71 vaccine demonstrated equivalence in immunogenicity among healthy children, with 95% CIs of the log difference in GMTs between -0.176 and 0.176.
Synapse has enriched 10 related papers. Consider them for comparative context: